Nutrition in critical illness: energy, protein and enteral feeding strategy

Clinical scope and why this matters

Nutrition in critical illness should be approached with a defined clinical question, a severity assessment and an explicit search for time-critical alternatives. The initial plan should connect symptoms and examination to targeted investigations, while recognising that a normal single test may not exclude evolving or intermittent disease. Treatment should be revised when the clinical trajectory differs from expectation. Nutrition care should distinguish inadequate intake from malabsorption, increased requirements and altered metabolism. Screening is only useful when followed by a practical plan for route, energy and protein delivery, electrolyte safety, micronutrients and monitoring.

Recognition and immediate priorities

Start by identifying physiological instability, rapidly progressive symptoms, severe pain, neurological or vascular compromise, sepsis, major bleeding, airway risk or another feature that changes the timescale of care. A focused first-pass assessment should distinguish routine pathways from cases needing emergency treatment, monitoring, imaging, procedure or specialist involvement.

History and examination

Clarify onset, progression, precipitating factors, previous episodes, relevant procedures, medicines, allergies, pregnancy status where relevant, comorbidity and baseline function. Examination should be directed by the anatomy and expected complications of the condition, while documenting clinically important negative findings that make dangerous alternatives less likely.

Sponsored

Assessment and diagnostic strategy

Choose investigations to answer specific questions: confirm the diagnosis, define severity, identify complications or establish a safe treatment option. Review previous results and trends where available. Interpret borderline findings against pre-test probability, test performance and timing rather than treating a numerical threshold as proof in isolation.

Management principles

Management should address the underlying process, symptoms, preventable complications and patient priorities. Before prescribing or performing a procedure, review contraindications, interactions, organ function, bleeding or thrombosis risk and practical feasibility. Where evidence supports several reasonable strategies, explain expected benefit, burden, uncertainty and the consequences of deferring treatment.

Escalation and high-risk situations

Escalate for physiological deterioration, organ dysfunction, uncontrolled symptoms, failure of initial treatment, or when diagnostic uncertainty carries substantial potential harm. If the required expertise, imaging, monitoring or procedural capability is not locally available, obtain specialist advice or arrange transfer before deterioration removes options.

International practice across English-speaking health systems

Across the UK, United States, Canada, Australia, New Zealand and Ireland, the underlying clinical reasoning is often shared while referral thresholds, medicine licensing, public-health duties, procedural pathways, screening programmes and legal requirements can differ. Use the current local formulary, regulator and specialty guideline for jurisdiction-specific detail. Where recommendations diverge, make the difference explicit rather than assuming that one national pathway applies internationally.

Monitoring, follow-up and prevention

Follow-up should have a defined purpose: confirmation of response, detection of complications, treatment monitoring, prevention or reassessment of the diagnosis. Define what will be measured and what result would trigger a change. Review adherence, adverse effects and barriers to care, and integrate prevention, vaccination, smoking or alcohol support, nutrition, physical activity, contraception or pregnancy planning, and psychosocial care when they materially affect outcome.

Common pitfalls and safety checks

Common avoidable errors include anchoring on an early diagnosis despite a changing clinical picture, using a test outside the population in which it is useful, failing to review medicines and organ function, and allowing ownership of abnormal results to become unclear. Reconsider the plan when response differs from expectation, a new symptom does not fit the original formulation, or treatment toxicity becomes more important than anticipated benefit. Diagnostic uncertainty should be documented and paired with explicit safety-netting rather than hidden by overconfident language.

Documentation, communication and shared decisions

Documentation should make clinical reasoning traceable. Record the working diagnosis and important alternatives, severity or risk assessment, clinically relevant negative findings, investigations that changed the plan, treatment started or withheld and the reason, and who owns pending results or follow-up. At transitions of care, reconcile medicines and clearly state warning symptoms, escalation instructions and the planned review interval. Shared decisions should describe the options discussed and the patient’s goals where more than one reasonable strategy exists.

Clinical reasoning and applicability

Clinical reasoning should remain iterative. Compare current findings with baseline, ask whether apparent severity is fully explained by the working diagnosis, and consider whether comorbidity or medication effects create a second simultaneous problem. When evidence is limited, explain the uncertainty and favour reversible, monitorable interventions while arranging the next diagnostic step. Multidisciplinary input is most valuable when it changes a decision, clarifies ownership or reduces a predictable safety risk.

Implementation, equity and continuity

Implementation should account for health literacy, language, access to medicines and diagnostics, disability, cultural context, rural or remote location, and continuity between primary, hospital and specialist care. A technically correct plan that cannot be followed is not a safe plan. Identify practical barriers early, simplify treatment where possible, and ensure the patient or caregiver knows how to obtain help if the course changes. Where follow-up depends on another service, document the referral, urgency and responsibility for acting if the appointment or result is delayed.

Practice points for multidisciplinary care

Keep the clinical question explicit at every stage. Before discharge, transfer or treatment escalation, ask what dangerous alternative remains plausible, what objective sign would demonstrate failure of the current plan, and who will act on that sign. The aim is not maximal testing; it is a defensible sequence of decisions that improves safety and makes later review easier.

Evidence interpretation and treatment choice

Guidelines should be applied to the patient in front of the clinician rather than copied as a checklist. Consider whether the evidence population resembles the current patient, whether the expected benefit is clinically important, and whether comorbidity, frailty, pregnancy, organ dysfunction or concurrent treatment changes the balance of benefit and harm. When recommendations from major bodies differ, identify the reason where possible, such as evidence date, resource setting, threshold preferences or medicine availability. Document why a chosen pathway is appropriate and avoid presenting a jurisdiction-specific recommendation as universal.

Transitions of care and handover safety

Transitions between emergency, inpatient, outpatient, primary-care and specialist settings create predictable opportunities for error. Handover should identify the active problem, unresolved diagnostic questions, medicines started or stopped, monitoring that remains outstanding and the exact trigger for earlier review. The receiving clinician should be able to understand what has already been considered without reconstructing the entire episode. Patients and caregivers need a concise explanation of expected recovery, warning features, how to access urgent help and which service owns follow-up.

Quality improvement and review

A high-quality pathway should be reviewable after the event. Teams can examine delays to recognition, inappropriate testing, missed contraindications, communication failures, avoidable readmission and whether follow-up occurred at the intended interval. Where repeated problems are identified, standardised order sets, checklists, referral criteria or patient information may reduce variation, but they should preserve clinical judgement. Resource pages should be reviewed when major guidance changes, new safety alerts emerge or the balance of treatment options materially shifts.

Sponsored

Special populations and individualisation

Individualisation is particularly important for older adults, children and adolescents, pregnancy, severe frailty, immunocompromise, advanced kidney or liver disease, and people taking multiple interacting medicines. Thresholds for investigation, treatment intensity and monitoring may need adjustment, and the harms of transfer or invasive intervention may carry different weight. Where evidence is sparse, seek relevant specialist input and make the uncertainty visible. Capacity, consent, family involvement and accessibility needs should be handled according to local law and the patient’s preferences.

Patient information and self-management

Patient information should match the decisions that actually need to be made. Explain the likely course, what treatment is intended to achieve, common adverse effects or complications, and which symptoms require urgent reassessment. Written or digital instructions are particularly useful when care involves staged medication changes, wound or device care, rehabilitation, exposure avoidance or home monitoring. Encourage questions and check understanding rather than assuming that provision of information is equivalent to informed participation.